A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Abstract

The use of novel therapies, such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs; ie, isatuximab, daratumumab, elotuzumab), has significantly improved the outcomes of multiple myeloma (MM) patients. However, MM remains largely incurable, with the majority of patients becoming refractory to available therapies and eventually relapsing.

Keywords

• isatuximab monotherapy
• daratumumab
• multiple myeloma